<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3530">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03871491</url>
  </required_header>
  <id_info>
    <org_study_id>CP Azithromycin</org_study_id>
    <nct_id>NCT03871491</nct_id>
  </id_info>
  <brief_title>Azithromycin-Prevention in Labor Use Study (A-PLUS)</brief_title>
  <official_title>Prevention of Maternal and Neonatal Death/Infections With a Single Oral Dose of Azithromycin in Women in Labor (in Low- and Middle-income Countries): a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NICHD Global Network for Women's and Children's Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Teaching Hospital, Lusaka, Zambia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kinshasa School of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Nutrition of Central America and Panama</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Centre for Diarrhoeal Disease Research, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aga Khan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lata Medical Research Foundation, Nagpur</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Moi Univeristy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RTI International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KLE University's Jawaharlal Nehru Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NICHD Global Network for Women's and Children's Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Maternal and neonatal infections are among the most frequent causes of maternal and neonatal
      deaths, and current antibiotic strategies have not been effective in preventing many of these
      deaths. Recently, a randomized clinical trial conducted in a single site in The Gambia showed
      that treatment with oral dose of 2 g azithromycin vs. placebo for all women in labor reduced
      selected maternal and neonatal infections. However, it is unknown if this therapy reduces
      maternal and neonatal sepsis and mortality. The A-PLUS trial includes two primary hypotheses,
      a maternal hypothesis and a neonatal hypothesis. First, a single, prophylactic intrapartum
      oral dose of 2 g azithromycin given to women in labor will reduce maternal death or sepsis.
      Second, a single, prophylactic intrapartum oral dose of 2 g azithromycin given to women in
      labor will reduce intrapartum/neonatal death or sepsis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The A-PLUS Trial is a randomized, placebo-controlled, parallel multicenter clinical trial.
      The study intervention is a single, prophylactic intrapartum oral dose of 2 g azithromycin,
      with a comparison with a single intrapartum oral dose of an identical appearing placebo. For
      the A-PLUS randomized control trial (RCT), a total of 34,000 laboring women from eight
      research sites in sub-Saharan Africa, South Asia, and Latin America will be randomized with
      one-to-one ratio to intervention/placebo. In response to the global coronavirus pandemic,
      research sites will also collect data on COVID-19 signs/symptoms, diagnosis, and treatment in
      order to estimate the incidence of infection and evaluate the impact of the pandemic on the
      target population.

      Prior to the initiation of the A-PLUS RCT, research sites will conduct an observational pilot
      study using the RCT's planned infrastructure in order to characterize the current practices
      at participating research facilities and optimize the identification of suspected infection
      for the RCT. The information obtained in the pilot study will be used to validate estimates
      of intrapartum deaths, maternal sepsis, and neonatal sepsis used in the sample size
      calculations for the RCT. Finally, the pilot study will allow the research sites to inventory
      and upgrade local capacity to conduct routine cultures during the RCT.

      A maximum of 16,000 women, separate from the sample for the main trial, will be enrolled in
      the pilot, across all eight research sites, with no more than 2000 women enrolled at any
      individual site. Research sites will be eligible to transition to the RCT when a minimum of
      600 participants have been enrolled in the pilot study with evidence of (a) high rates of
      follow-up; (2) acceptable data quality and completeness; and (3) there are no concerns about
      identification and reporting of infection.

      Given the clinical benefits of intrapartum azithromycin so far reported in two trials and the
      likelihood that it may become the usual practice if the investigator's large RCT confirms the
      reported benefits, it is important to monitor antibiotic resistance to determine the safety
      of azithromycin prophylaxis. Therefore, the RCT will also include an ancillary study
      (referred to as the antimicrobial resistance (AMR) sub-study) to monitor antimicrobial
      resistance and maternal and newborn microbiome effects of the single dose of prophylactic
      azithromycin using the following methodology

        1. For all mothers enrolled in the RCT and their infants:

           a. Routine clinical monitoring at baseline and three post-partum time points (3 days, 7
           days, and 42 days), with culture and sensitivity testing in cases of suspected bacterial
           infections;

        2. Among a subset of 1000 randomly selected maternal-infant dyads:

             1. Serial susceptibility monitoring of antimicrobial resistance patterns (including
                azithromycin resistance) from selected maternal and newborn flora through culture
                and sensitivity testing. Serial monitoring will be conducted at baseline and three
                post-partum time points (1 week, 6 weeks, and 3 months).

             2. Serial microbiome collection and storage of specimens for future testing to monitor
                maternal and newborn microbiome status of selected sites.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, placebo-controlled, parallel multicenter clinical trial. Women in labor will be randomized with one-to-one ratio to intervention/placebo.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Both the azithromycin and placebo will be procured from the same manufacturer. The packaging will be standardized across sites and will be labeled as: &quot;Azithromycin 2 g or Placebo&quot;, with the expiration data and a unique identifier.
Clinical and research staff as well as the women will be masked to treatment status unless there is a serious adverse event potentially related to the treatment modality that requires unmasking for safety reasons. There will be one pharmacist at each site who will monitor randomization, drug supply, and safety. If concerns about randomization or participant safety are identified, the data coordinating center will authorize and instruct the study pharmacist to apply un-masking procedures.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Maternal: Incidence of maternal death or sepsis within 6 weeks (42 days) post-delivery in intervention vs. placebo group.</measure>
    <time_frame>within 6 weeks (42 days)</time_frame>
    <description>Incidence of maternal death or sepsis within 6 weeks (42 days) post-delivery in intervention vs. placebo group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neonatal: Incidence of intrapartum/neonatal death or sepsis within 4 weeks (28 days) post-delivery in intervention vs. placebo group</measure>
    <time_frame>4 weeks (28 days) post-delivery</time_frame>
    <description>Incidence of intrapartum/neonatal death or sepsis within 4 weeks (28 days) post-delivery in intervention vs. placebo group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of chorioamnionitis</measure>
    <time_frame>prior to delivery</time_frame>
    <description>Fever (&gt;100.4°F/38°C) in addition to one or more of the following: fetal tachycardia ≥160 bpm, maternal tachycardia &gt;100 bpm, tender uterus between contractions, or purulent/foul smelling discharge from uterus prior to delivery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of endometritis</measure>
    <time_frame>within 42 days post-delivery</time_frame>
    <description>Fever (&gt;100.4°F/38°C) in addition to one or more of maternal tachycardia &gt;100 bpm, tender uterine fundus, or purulent/foul smelling discharge from uterus after delivery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of other infections</measure>
    <time_frame>within 42 days post-delivery</time_frame>
    <description>Wound infection (Purulent infection of a perineal or Cesarean wound with or without fever. In the absence of purulence, requires presence of fever &gt;100.4°F/38°C and at least one of the following signs of local infection: pain or tenderness, swelling, heat, or redness around the incision/laceration); Abdominopelvic abscess (Evidence of pus in the abdomen or pelvis noted during open surgery, interventional aspiration or imaging); Pneumonia (Fever &gt;100.4°F/38°C and clinical symptoms suggestive of lung infection including cough and/or tachypnea &gt;24 breaths/min or radiological confirmation); Pyelonephritis (Fever &gt;100.4°F/38°C and one or more of the following: urinalysis/dip suggestive of infection, costovertebral angle tenderness, or confirmatory urine culture); Mastitis/breast abscess or infection (Fever &gt;100.4°F/38°C and one or more of the following: breast pain, swelling, warmth, redness, or purulent drainage).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of use of subsequent maternal antibiotic therapy</measure>
    <time_frame>after randomization to 42 days post-delivery</time_frame>
    <description>Use of subsequent maternal antibiotic therapy after randomization to 42 days postpartum for any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal initial hospital length of stay</measure>
    <time_frame>within 42 days post-delivery</time_frame>
    <description>Time from drug administration until initial discharge after delivery (time may vary by site).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of maternal readmissions</measure>
    <time_frame>within 42 days post-delivery</time_frame>
    <description>Maternal readmissions within 42 days of delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of maternal admission to special care units</measure>
    <time_frame>within 42 days post-delivery</time_frame>
    <description>Maternal admission to special care units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of maternal unscheduled visit for care</measure>
    <time_frame>within 42 days post-delivery</time_frame>
    <description>Maternal unscheduled visit for care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of maternal GI symptoms</measure>
    <time_frame>within 42 days post-delivery</time_frame>
    <description>Maternal GI symptoms including nausea, vomiting, and diarrhea and other reported side effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of maternal death due to sepsis</measure>
    <time_frame>within 42 days post-delivery</time_frame>
    <description>Maternal death due to sepsis using the Global Network algorithm for cause of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of other neonatal infections (e.g. eye infection, skin infection)</measure>
    <time_frame>within 42 days post-delivery</time_frame>
    <description>Incidence of other neonatal infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal initial hospital length of stay</measure>
    <time_frame>within 28 days of delivery</time_frame>
    <description>Neonatal initial hospital length of stay, defined as time of delivery until initial discharge (time may vary by site).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of neonatal readmissions</measure>
    <time_frame>within 42 days of delivery</time_frame>
    <description>Neonatal readmissions within 42 days of delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of neonatal admission to special care units</measure>
    <time_frame>within 28 days of delivery</time_frame>
    <description>Neonatal admission to special care units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of neonatal unscheduled visit for care</measure>
    <time_frame>within 42 days post-delivery</time_frame>
    <description>Neonatal unscheduled visit for care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of neonatal death due to sepsis</measure>
    <time_frame>within 28 days of delivery</time_frame>
    <description>Neonatal death due to sepsis using the Global Network algorithm for causes of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of pyloric stenosis within 42 days of delivery</measure>
    <time_frame>within 42 days of delivery</time_frame>
    <description>Pyloric stenosis within 42 days of delivery, defined as clinical suspicion based on severe vomiting leading to death, surgical intervention (pyloromyotomy) as verified from medical records, or radiological confirmation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34000</enrollment>
  <condition>Maternal Death</condition>
  <condition>Maternal Infections Affecting Fetus or Newborn</condition>
  <condition>Neonatal SEPSIS</condition>
  <condition>Maternal Sepsis During Labor</condition>
  <condition>Neonatal Death</condition>
  <condition>Postpartum Sepsis</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study intervention is a single 2 g dose of directly observed oral azithromycin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>By random allocation, participants will receive four oral placebo pills containing a non-antimicrobial agent directly after randomization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>The study intervention is a single 2 g dose of directly observed oral azithromycin, to be administered as four 500 mg pills or tablets directly after randomization. By random allocation, participants will receive 2 g of oral azithromycin.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identical appearing placebo, administered as a single oral dose directly after randomization.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women in labor ≥28 weeks Gestational Age (GA) (by best estimate) with a
             pregnancy with one or more live fetuses who plan to deliver vaginally in a facility.

          -  Admitted to health facility with clear plan for spontaneous or induced delivery.

          -  Live fetus must be confirmed via a fetal heart rate by Doptone prior to randomization.

          -  ≥18 years of age or minors 14-17 years of age in countries where married or pregnant
             minors (or their authorized representatives) are legally permitted to give consent.

          -  Have provided written informed consent.

          -  Pregnant women in labor ≥28 weeks GA (by best estimate) with a pregnancy with one or
             more live fetuses who plan to deliver vaginally in a facility.

          -  Admitted to health facility with clear plan for spontaneous or induced delivery.

          -  Live fetus must be confirmed via presence of a fetal heart rate prior to
             randomization.

          -  ≥18 years of age or minors 14-17 years of age in countries where married or pregnant
             minors (or their authorized representatives) are legally permitted to give consent.

          -  Have provided written informed consent [Note: written informed consent may be obtained
             during antenatal care, but verbal re-confirmation may be needed (per local
             regulations) at the time of randomization].

        Exclusion Criteria:

          -  Non-emancipated minors (as per local regulations)

          -  Evidence of chorioamnionitis or other infection requiring antibiotic therapy at time
             of eligibility (however, women given single prophylactic antibiotics with no plans to
             continue after delivery should not be excluded).

          -  Arrhythmia or known history of cardiomyopathy.

          -  Allergy to azithromycin or other macrolides that is self-reported or documented in the
             medical record.

          -  Any use of azithromycin, erythromycin, or other macrolide in the 3 days or less prior
             to randomization.

          -  Plan for cesarean delivery prior to randomization.

          -  Preterm labor undergoing management with no immediate plan to proceed to delivery.

          -  Advanced stage of labor (&gt;6 cm or 10 cm cervical dilation per local standards) and
             pushing or too distressed to understand, confirm, or give informed consent regardless
             of cervical dilation.

          -  Are not capable of giving consent due to other health problems such as obstetric
             emergencies (for example, antepartum hemorrhage) or mental disorder.

          -  Any other medical conditions that may be considered a contraindication per the
             judgment of the site investigator.

          -  Previous randomization in the trial.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marion Koso-Thomas, MD</last_name>
    <role>Study Director</role>
    <affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth McClure, PhD</last_name>
    <phone>919 316 3773</phone>
    <email>mcclure@rti.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tracy Nolen, DrPH</last_name>
    <phone>919 541 7467</phone>
    <email>tnolen@rti.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ICDDRB</name>
      <address>
        <city>Dhaka</city>
        <zip>1212</zip>
        <country>Bangladesh</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Principal Investigator</last_name>
      <email>rhaque@icddrb.org</email>
    </contact>
    <investigator>
      <last_name>Rashidul Haque, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kinshasa School of Public Health</name>
      <address>
        <city>Kinshasa</city>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoinette Tshefu, MD, MPH, PhD</last_name>
      <email>antotshe@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Antoinette Tshefu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute for Nutrition of Central America and Panama (INCAP)</name>
      <address>
        <city>Guatemala City</city>
        <zip>01011</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lester Figueroa, MD</last_name>
      <email>lfigueroa@incap.int</email>
    </contact>
    <investigator>
      <last_name>Lester Figueroa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jawaharlal Nehru Medical College</name>
      <address>
        <city>Belagavi</city>
        <zip>590 010</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shivaprasad S. Goudar, MD, MHPE</last_name>
      <phone>011 91 831 2409 2055</phone>
      <email>sgoudar@jnmc.edu</email>
    </contact>
    <investigator>
      <last_name>Shivaprasad S. Goudar, MD, MHPE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lata Medical Research Foundation</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Archana Patel, MD, DNB, MSCE</last_name>
      <email>dr_apatel@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Archana Patel, MD, DNB, MSCE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moi University School of Medicine</name>
      <address>
        <city>Eldoret</city>
        <zip>30100</zip>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabian Esamai, MBChB, MMed, PhD</last_name>
      <phone>011 254 733 836 410</phone>
      <email>fesamai2007@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Fabian Esamai, MBChB, MMed, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Aga Khan University</name>
      <address>
        <city>Karachi</city>
        <zip>74800</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Saleem, MD</last_name>
      <email>Sarah.saleem@aku.edu</email>
    </contact>
    <investigator>
      <last_name>Sarah Saleem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Teaching Hospital</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elwyn Chomba, MBChB, DCH, MRCP</last_name>
      <email>echomba@zamnet.zm</email>
    </contact>
    <investigator>
      <last_name>Elwyn Chomba, MBChB, DCH, MRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Bangladesh</country>
    <country>Congo, The Democratic Republic of the</country>
    <country>Guatemala</country>
    <country>India</country>
    <country>Kenya</country>
    <country>Pakistan</country>
    <country>Zambia</country>
  </location_countries>
  <reference>
    <citation>World Health Organization. (2015). WHO recommendations for the prevention and treatment of maternal peripartum infections. Retrieved August 22, 2018, from http://www.who.int/reproductivehealth/publications/maternal_perinatal_health/peripartum-infections-guidelines</citation>
  </reference>
  <reference>
    <citation>Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, Cousens S, Mathers C, Black RE. Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet. 2015 Jan 31;385(9966):430-40. doi: 10.1016/S0140-6736(14)61698-6. Epub 2014 Sep 30. Erratum in: Lancet. 2015 Jan 31;385(9966):420. Erratum in: Lancet. 2016 Jun 18;387(10037):2506.</citation>
    <PMID>25280870</PMID>
  </reference>
  <reference>
    <citation>African Neonatal Sepsis Trial (AFRINEST) group, Tshefu A, Lokangaka A, Ngaima S, Engmann C, Esamai F, Gisore P, Ayede AI, Falade AG, Adejuyigbe EA, Anyabolu CH, Wammanda RD, Ejembi CL, Ogala WN, Gram L, Cousens S. Simplified antibiotic regimens compared with injectable procaine benzylpenicillin plus gentamicin for treatment of neonates and young infants with clinical signs of possible serious bacterial infection when referral is not possible: a randomised, open-label, equivalence trial. Lancet. 2015 May 2;385(9979):1767-1776. doi: 10.1016/S0140-6736(14)62284-4. Epub 2015 Apr 1.</citation>
    <PMID>25842221</PMID>
  </reference>
  <reference>
    <citation>Baqui AH, Saha SK, Ahmed AS, Shahidullah M, Quasem I, Roth DE, Samsuzzaman AK, Ahmed W, Tabib SM, Mitra DK, Begum N, Islam M, Mahmud A, Rahman MH, Moin MI, Mullany LC, Cousens S, El Arifeen S, Wall S, Brandes N, Santosham M, Black RE; Projahnmo Study Group in Bangladesh. Safety and efficacy of alternative antibiotic regimens compared with 7 day injectable procaine benzylpenicillin and gentamicin for outpatient treatment of neonates and young infants with clinical signs of severe infection when referral is not possible: a randomised, open-label, equivalence trial. Lancet Glob Health. 2015 May;3(5):e279-87. doi: 10.1016/S2214-109X(14)70347-X. Epub 2015 Apr 1.</citation>
    <PMID>25841891</PMID>
  </reference>
  <reference>
    <citation>Mir F, Nisar I, Tikmani SS, Baloch B, Shakoor S, Jehan F, Ahmed I, Cousens S, Zaidi AK. Simplified antibiotic regimens for treatment of clinical severe infection in the outpatient setting when referral is not possible for young infants in Pakistan (Simplified Antibiotic Therapy Trial [SATT]): a randomised, open-label, equivalence trial. Lancet Glob Health. 2017 Feb;5(2):e177-e185. doi: 10.1016/S2214-109X(16)30335-7. Epub 2016 Dec 15.</citation>
    <PMID>27988146</PMID>
  </reference>
  <reference>
    <citation>Zaidi AK, Tikmani SS, Sultana S, Baloch B, Kazi M, Rehman H, Karimi K, Jehan F, Ahmed I, Cousens S. Simplified antibiotic regimens for the management of clinically diagnosed severe infections in newborns and young infants in first-level facilities in Karachi, Pakistan: study design for an outpatient randomized controlled equivalence trial. Pediatr Infect Dis J. 2013 Sep;32 Suppl 1:S19-25. doi: 10.1097/INF.0b013e31829ff7aa.</citation>
    <PMID>23945571</PMID>
  </reference>
  <reference>
    <citation>Gibbs RS. Clinical risk factors for puerperal infection. Obstet Gynecol. 1980 May;55(5 Suppl):178S-184S. Review.</citation>
    <PMID>6990333</PMID>
  </reference>
  <reference>
    <citation>World Health Organization. (2015). WHO Statement on Caesarean Section Rates. Retrieved August 22, 2018, from http://www.who.int/reproductivehealth/publications/maternal_perinatal_health/cs-statement/en/</citation>
  </reference>
  <reference>
    <citation>Mackeen AD, Packard RE, Ota E, Berghella V, Baxter JK. Timing of intravenous prophylactic antibiotics for preventing postpartum infectious morbidity in women undergoing cesarean delivery. Cochrane Database Syst Rev. 2014 Dec 5;(12):CD009516. doi: 10.1002/14651858.CD009516.pub2. Review.</citation>
    <PMID>25479008</PMID>
  </reference>
  <reference>
    <citation>Smaill FM, Grivell RM. Antibiotic prophylaxis versus no prophylaxis for preventing infection after cesarean section. Cochrane Database Syst Rev. 2014 Oct 28;(10):CD007482. doi: 10.1002/14651858.CD007482.pub3. Review.</citation>
    <PMID>25350672</PMID>
  </reference>
  <reference>
    <citation>Gyte GM, Dou L, Vazquez JC. Different classes of antibiotics given to women routinely for preventing infection at caesarean section. Cochrane Database Syst Rev. 2014 Nov 17;(11):CD008726. doi: 10.1002/14651858.CD008726.pub2. Review.</citation>
    <PMID>25402227</PMID>
  </reference>
  <reference>
    <citation>Tita AT, Rouse DJ, Blackwell S, Saade GR, Spong CY, Andrews WW. Emerging concepts in antibiotic prophylaxis for cesarean delivery: a systematic review. Obstet Gynecol. 2009 Mar;113(3):675-82. doi: 10.1097/AOG.0b013e318197c3b6. Review.</citation>
    <PMID>19300334</PMID>
  </reference>
  <reference>
    <citation>Tita AT, Szychowski JM, Boggess K, Saade G, Longo S, Clark E, Esplin S, Cleary K, Wapner R, Letson K, Owens M, Abramovici A, Ambalavanan N, Cutter G, Andrews W; C/SOAP Trial Consortium. Adjunctive Azithromycin Prophylaxis for Cesarean Delivery. N Engl J Med. 2016 Sep 29;375(13):1231-41. doi: 10.1056/NEJMoa1602044.</citation>
    <PMID>27682034</PMID>
  </reference>
  <reference>
    <citation>Oluwalana C, Camara B, Bottomley C, Goodier S, Bojang A, Kampmann B, Ceesay S, D'Alessandro U, Roca A. Azithromycin in Labor Lowers Clinical Infections in Mothers and Newborns: A Double-Blind Trial. Pediatrics. 2017 Feb;139(2). pii: e20162281. doi: 10.1542/peds.2016-2281.</citation>
    <PMID>28130432</PMID>
  </reference>
  <reference>
    <citation>World Health Organization. (2017). Statement on maternal sepsis. Retrieved Ausust 22, 2018, from http://www.who.int/reproductivehealth/publications/maternal_perinatal_health/maternalsepsis-statement/en/</citation>
  </reference>
  <reference>
    <citation>Reinhart K, Daniels R, Kissoon N, Machado FR, Schachter RD, Finfer S. Recognizing Sepsis as a Global Health Priority - A WHO Resolution. N Engl J Med. 2017 Aug 3;377(5):414-417. doi: 10.1056/NEJMp1707170. Epub 2017 Jun 28.</citation>
    <PMID>28658587</PMID>
  </reference>
  <reference>
    <citation>van Dillen J, Zwart J, Schutte J, van Roosmalen J. Maternal sepsis: epidemiology, etiology and outcome. Curr Opin Infect Dis. 2010 Jun;23(3):249-54. doi: 10.1097/QCO.0b013e328339257c. Review.</citation>
    <PMID>20375891</PMID>
  </reference>
  <reference>
    <citation>Roca A, Oluwalana C, Bojang A, Camara B, Kampmann B, Bailey R, Demba A, Bottomley C, D'Alessandro U. Oral azithromycin given during labour decreases bacterial carriage in the mothers and their offspring: a double-blind randomized trial. Clin Microbiol Infect. 2016 Jun;22(6):565.e1-9. doi: 10.1016/j.cmi.2016.03.005. Epub 2016 Mar 26.</citation>
    <PMID>27026482</PMID>
  </reference>
  <reference>
    <citation>Harper LM, Kilgore M, Szychowski JM, Andrews WW, Tita ATN. Economic Evaluation of Adjunctive Azithromycin Prophylaxis for Cesarean Delivery. Obstet Gynecol. 2017 Aug;130(2):328-334. doi: 10.1097/AOG.0000000000002129.</citation>
    <PMID>28697108</PMID>
  </reference>
  <reference>
    <citation>Andrews WW, Hauth JC, Cliver SP, Savage K, Goldenberg RL. Randomized clinical trial of extended spectrum antibiotic prophylaxis with coverage for Ureaplasma urealyticum to reduce post-cesarean delivery endometritis. Obstet Gynecol. 2003 Jun;101(6):1183-9.</citation>
    <PMID>12798523</PMID>
  </reference>
  <reference>
    <citation>Tita AT, Hauth JC, Grimes A, Owen J, Stamm AM, Andrews WW. Decreasing incidence of postcesarean endometritis with extended-spectrum antibiotic prophylaxis. Obstet Gynecol. 2008 Jan;111(1):51-6. doi: 10.1097/01.AOG.0000295868.43851.39.</citation>
    <PMID>18165392</PMID>
  </reference>
  <reference>
    <citation>Tita AT, Owen J, Stamm AM, Grimes A, Hauth JC, Andrews WW. Impact of extended-spectrum antibiotic prophylaxis on incidence of postcesarean surgical wound infection. Am J Obstet Gynecol. 2008 Sep;199(3):303.e1-3. doi: 10.1016/j.ajog.2008.06.068.</citation>
    <PMID>18771992</PMID>
  </reference>
  <reference>
    <citation>Watts DH, Eschenbach DA, Kenny GE. Early postpartum endometritis: the role of bacteria, genital mycoplasmas, and Chlamydia trachomatis. Obstet Gynecol. 1989 Jan;73(1):52-60.</citation>
    <PMID>2783262</PMID>
  </reference>
  <reference>
    <citation>Hoyme UB, Kiviat N, Eschenbach DA. Microbiology and treatment of late postpartum endometritis. Obstet Gynecol. 1986 Aug;68(2):226-32.</citation>
    <PMID>3737039</PMID>
  </reference>
  <reference>
    <citation>Emmons SL, Krohn M, Jackson M, Eschenbach DA. Development of wound infections among women undergoing cesarean section. Obstet Gynecol. 1988 Oct;72(4):559-64.</citation>
    <PMID>3419735</PMID>
  </reference>
  <reference>
    <citation>Roberts S, Maccato M, Faro S, Pinell P. The microbiology of post-cesarean wound morbidity. Obstet Gynecol. 1993 Mar;81(3):383-6.</citation>
    <PMID>8437791</PMID>
  </reference>
  <reference>
    <citation>Rosene K, Eschenbach DA, Tompkins LS, Kenny GE, Watkins H. Polymicrobial early postpartum endometritis with facultative and anaerobic bacteria, genital mycoplasmas, and Chlamydia trachomatis: treatment with piperacillin or cefoxitin. J Infect Dis. 1986 Jun;153(6):1028-37.</citation>
    <PMID>3701114</PMID>
  </reference>
  <reference>
    <citation>Andrews WW, Shah SR, Goldenberg RL, Cliver SP, Hauth JC, Cassell GH. Association of post-cesarean delivery endometritis with colonization of the chorioamnion by Ureaplasma urealyticum. Obstet Gynecol. 1995 Apr;85(4):509-14.</citation>
    <PMID>7898825</PMID>
  </reference>
  <reference>
    <citation>Keski-Nisula L, Kirkinen P, Katila ML, Ollikainen M, Suonio S, Saarikoski S. Amniotic fluid U. urealyticum colonization: significance for maternal peripartal infections at term. Am J Perinatol. 1997 Mar;14(3):151-6.</citation>
    <PMID>9259918</PMID>
  </reference>
  <reference>
    <citation>Yoon BH, Romero R, Park JS, Chang JW, Kim YA, Kim JC, Kim KS. Microbial invasion of the amniotic cavity with Ureaplasma urealyticum is associated with a robust host response in fetal, amniotic, and maternal compartments. Am J Obstet Gynecol. 1998 Nov;179(5):1254-60.</citation>
    <PMID>9822511</PMID>
  </reference>
  <reference>
    <citation>Ledger WJ. Prophylactic antibiotics in obstetrics-gynecology: a current asset, a future liability? Expert Rev Anti Infect Ther. 2006 Dec;4(6):957-64. Review.</citation>
    <PMID>17181412</PMID>
  </reference>
  <reference>
    <citation>World Health Organization. (2015). Guideline: Managing Possible Serious Bacterial Infection in Young Infants When Referral is not Feasible. Retrieved August 22, 2018, from http://apps.who.int/iris/bitstream/handle/10665/181426/9789241509268_eng.pdf;jsessionid=F74B437689D1CB960E2544DDF53FE5A6?sequence=1</citation>
  </reference>
  <reference>
    <citation>Sutton AL, Acosta EP, Larson KB, Kerstner-Wood CD, Tita AT, Biggio JR. Perinatal pharmacokinetics of azithromycin for cesarean prophylaxis. Am J Obstet Gynecol. 2015 Jun;212(6):812.e1-6. doi: 10.1016/j.ajog.2015.01.015. Epub 2015 Jan 13.</citation>
    <PMID>25595580</PMID>
  </reference>
  <reference>
    <citation>Eberly MD, Eide MB, Thompson JL, Nylund CM. Azithromycin in early infancy and pyloric stenosis. Pediatrics. 2015 Mar;135(3):483-8. doi: 10.1542/peds.2014-2026.</citation>
    <PMID>25687145</PMID>
  </reference>
  <reference>
    <citation>Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012 May 17;366(20):1881-90. doi: 10.1056/NEJMoa1003833.</citation>
    <PMID>22591294</PMID>
  </reference>
  <reference>
    <citation>Svanström H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med. 2013 May 2;368(18):1704-12. doi: 10.1056/NEJMoa1300799.</citation>
    <PMID>23635050</PMID>
  </reference>
  <reference>
    <citation>Hoffman MK, Goudar SS, Kodkany BS, Goco N, Koso-Thomas M, Miodovnik M, McClure EM, Wallace DD, Hemingway-Foday JJ, Tshefu A, Lokangaka A, Bose CL, Chomba E, Mwenechanya M, Carlo WA, Garces A, Krebs NF, Hambidge KM, Saleem S, Goldenberg RL, Patel A, Hibberd PL, Esamai F, Liechty EA, Silver R, Derman RJ. A description of the methods of the aspirin supplementation for pregnancy indicated risk reduction in nulliparas (ASPIRIN) study. BMC Pregnancy Childbirth. 2017 May 3;17(1):135. doi: 10.1186/s12884-017-1312-x.</citation>
    <PMID>28468653</PMID>
  </reference>
  <reference>
    <citation>Goldenberg RL, Saleem S, Ali S, Moore JL, Lokangako A, Tshefu A, Mwenechanya M, Chomba E, Garces A, Figueroa L, Goudar S, Kodkany B, Patel A, Esamai F, Nsyonge P, Harrison MS, Bauserman M, Bose CL, Krebs NF, Hambidge KM, Derman RJ, Hibberd PL, Liechty EA, Wallace DD, Belizan JM, Miodovnik M, Koso-Thomas M, Carlo WA, Jobe AH, McClure EM. Maternal near miss in low-resource areas. Int J Gynaecol Obstet. 2017 Sep;138(3):347-355. doi: 10.1002/ijgo.12219. Epub 2017 Jun 13.</citation>
    <PMID>28513837</PMID>
  </reference>
  <reference>
    <citation>Bonet M, Souza JP, Abalos E, Fawole B, Knight M, Kouanda S, Lumbiganon P, Nabhan A, Nadisauskiene R, Brizuela V, Metin Gülmezoglu A. The global maternal sepsis study and awareness campaign (GLOSS): study protocol. Reprod Health. 2018 Jan 30;15(1):16. doi: 10.1186/s12978-017-0437-8.</citation>
    <PMID>29382352</PMID>
  </reference>
  <reference>
    <citation>Albright CM, Has P, Rouse DJ, Hughes BL. Internal Validation of the Sepsis in Obstetrics Score to Identify Risk of Morbidity From Sepsis in Pregnancy. Obstet Gynecol. 2017 Oct;130(4):747-755. doi: 10.1097/AOG.0000000000002260.</citation>
    <PMID>28885400</PMID>
  </reference>
  <reference>
    <citation>Bowyer L, Robinson HL, Barrett H, Crozier TM, Giles M, Idel I, Lowe S, Lust K, Marnoch CA, Morton MR, Said J, Wong M, Makris A. SOMANZ guidelines for the investigation and management sepsis in pregnancy. Aust N Z J Obstet Gynaecol. 2017 Oct;57(5):540-551. doi: 10.1111/ajo.12646. Epub 2017 Jul 3.</citation>
    <PMID>28670748</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 5, 2019</study_first_submitted>
  <study_first_submitted_qc>March 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2019</study_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>maternal sepsis</keyword>
  <keyword>maternal death</keyword>
  <keyword>neonatal sepsis</keyword>
  <keyword>neonatal death</keyword>
  <keyword>azithromycin</keyword>
  <keyword>Democratic Republic of Congo</keyword>
  <keyword>Zambia</keyword>
  <keyword>Guatemala</keyword>
  <keyword>Bangladesh</keyword>
  <keyword>India</keyword>
  <keyword>Pakistan</keyword>
  <keyword>Kenya</keyword>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Neonatal Sepsis</mesh_term>
    <mesh_term>Pregnancy Complications, Infectious</mesh_term>
    <mesh_term>Puerperal Infection</mesh_term>
    <mesh_term>Perinatal Death</mesh_term>
    <mesh_term>Maternal Death</mesh_term>
    <mesh_term>Death</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

